Boehringer Ingelheim launches Phase II trial for novel oral Geographic Atrophy treatment

Boehringer Ingelheim has initiated the JADE Phase II clinical study to assess the efficacy and safety of a new investigational drug, BI 1584862, for treating geographic atrophy (GA). This advanced form of age-related macular degeneration (AMD) is a leading cause of irreversible vision loss, affecting over five million individuals globally, with more than 40% classified as legally blind. GA significantly impacts patients' independence, mental well-being, and overall quality of life. Despite the prevalence of GA, there is a significant lack of treatments to halt or slow its progression, emphasizing the urgent need for innovative therapies.

BI 1584862 is a phospholipid modulator designed to potentially offer a novel oral treatment option for GA by preserving vision in patients. This investigational compound represents the second eye health asset by Boehringer Ingelheim to progress to Phase II trials. Previously, the compound BI 771716 was developed, which is a highly specific antibody fragment created to efficiently penetrate retinal layers and target GA pathology.

BI 771716, distinguished by its molecular properties and developed using CDR-Life's proprietary technology, aims to achieve remarkable efficacy against GA. Boehringer Ingelheim's ongoing research in this area reflects its commitment to addressing the diverse needs of GA patients and the medical community at large. The company's strategy involves two distinct clinical trials for BI 1584862 and BI 771716, focusing on different mechanisms to tailor solutions for individuals with GA.

Dr. Karl Csaky, the principal investigator of the Phase II trial, underscores the profound impact of vision loss associated with GA, particularly among older adults. This condition makes daily activities more challenging and burdens the lives of patients, caregivers, and society as a whole. The exploration of oral treatments by Boehringer Ingelheim could simplify treatment regimens and concurrently address both eyes in patients with bilateral disease, reducing the burden on patients and caregivers.

Dr. Patrick Bussfeld from Boehringer Ingelheim emphasizes the company's aim to provide personalized treatment options that improve the quality of life for those living with GA. By investigating multiple compounds, they strive to offer more individualized care, ultimately enhancing patients' lives.

The announcement of these clinical trials aligns with the Association for Research in Vision and Ophthalmology (ARVO) Annual meeting, where Boehringer Ingelheim will present various abstracts from its diverse Eye Health portfolio. This presentation further underscores the company's dedication to addressing unmet needs in retinal conditions.

Geographic atrophy, a severe manifestation of AMD, progresses slowly but can lead to permanent vision loss. More than five million people are currently affected by GA, with the prevalence of the condition rising significantly in aging populations. The disease primarily results in moderate to severe central vision loss, impacting daily activities such as driving, reading, and social interaction. These challenges can lead to social isolation and mental health issues, including depression and anxiety.

Boehringer Ingelheim, a global biopharmaceutical company, is dedicated to creating innovative therapies for areas with high unmet medical needs. As a leader in research and development, the company maintains a long-term perspective, with sustainability embedded throughout its operations. With over 54,500 employees worldwide, Boehringer Ingelheim continues to focus on improving health outcomes and sustainability across its markets.